Opendata, web and dolomites

CTC-MAL

Isolation of rare circulating tumor cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CTC-MAL" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 149˙375 €
 EC max contribution 149˙375 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2019-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 149˙375.00

Map

 Project objective

In 2013 I was awarded an ERC consolidator grant to pursue a novel cancer targeting concept using a recombinant malaria protein. As an ERC grantee I verified the malaria protein (rVAR2) binds to this distinct cancer expressed molecule (CSA) in hundreds of cancer cell lines and thousands of tissue biopsies. Our research demonstrate a pivotal role of CSA in cancer cell migration and thus in the formation of metastasis. Circulating tumor cells (CTCs) are cancer cells escaping the primary tumor with the capacity to settle and form a metastasis in distant organs. Isolation of CTC is thus a very attractive non-invasive measure of the stage of a given cancer and provides the opportunity to do direct phenotypic analyses. However CTCs are in most cases very rare (10 cells pr 1ml blood) and does not uniformly distinguish themselves from normal blood cells. Our preliminary data show that rVAR2 very effectively can be used to isolate CTCs from diverse types of cancer with unprecedented specificity and sensitivity. Such a tool could have wide impact for cancer patients because it could sharpen diagnosis, increase prognostic ability, monitor drug efficacy and facilitate molecular characterization of individual cancers with implications for personalized medicine and basic cancer research. The aim of the ERC PoC project is to A) prepare for establishment of a separate company with a strategic product plan and B) further develop and validate the methodology enabling diagnosis, prognosis and guide treatment.

 Publications

year authors and title journal last update
List of publications.
2018 Mette Ø. Agerbæk, Sara R. Bang-Christensen, Ming-Hsin Yang, Thomas M. Clausen, Marina A. Pereira, Shreya Sharma, Sisse B. Ditlev, Morten A. Nielsen, Swati Choudhary, Tobias Gustavsson, Poul H. Sorensen, Tim Meyer, David Propper, Jonathan Shamash, Thor G. Theander, Alexandra Aicher, Mads Daugaard, Christopher Heeschen, Ali Salanti
The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner
published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-018-05793-2
Nature Communications 9/1 2019-10-28

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CTC-MAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CTC-MAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More